Using artificial intelligence to predict targeted therapy success for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study uses artificial intelligence to predict how well EGFR-targeted therapy will work for people with certain lung cancers. It looks at your imaging and genetic information to help guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You had surgery to remove lung cancer and the surgeon was able to take out all of it (no cancer cells left behind)
- Your cancer was at stage IB, II, or IIIA after surgery
- Your cancer is a type called adenocarcinoma
- You have a specific EGFR gene change (either 19del or L858R)
- You are taking or plan to take an EGFR-targeted pill after surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether changes in tiny particles in your blood (called exosomes) can show how well targeted therapy is working for lung cancer with an EGFR mutation. You may be eligible if you have this type of lung cancer and are starting your first treatment with a targeted drug.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
This trial tests whether a targeted therapy pill (EGFR-TKI) can control small spots in the other lung after surgery for early-stage lung cancer. It's for people whose cancer has a specific EGFR gene change and who still have suspicious spots in the opposite lung after one side is removed.
This trial looks at how well a targeted therapy works before surgery for people with EGFR-mutated non-small cell lung cancer. It aims to understand the link between a heart rhythm measure (RVT) and patient outcomes.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
This study tests whether using a blood test to detect leftover tumor DNA after surgery can guide extra treatment for people with EGFR-mutant lung cancer. The goal is to see if starting or avoiding targeted therapy based on this test improves outcomes.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.